Beginning in December, adults in the state of Connecticut will be allowed to buy up to one-half an ounce of cannabis in one retail transaction. This comes after the state doubled its purchase limit from quarter of an ounce of marijuana.

The state’s Department of Consumer Protection announced the scheduled increase last week, explaining that it was the result of a continuing analysis of demand and supply and was designed to make certain businesses maintain sufficient supply for both medical cannabis patients and adult-use consumers.

It should be noted, however, that the limits imposed on medical cannabis remain unchanged.

The state department’s commissioner, Bryan T. Cafferelli, added that as more production companies, retailers and other licensees in the supply chain came online, the industry’s capacity had increased. Cafferelli noted that they were confident the measured approach to recreational sales had created a healthy market for businesses as well as a fair and safe marketplace for both medical cannabis patients and adult-use marijuana consumers.

Currently, possession of marijuana in the state is capped at one and a half ounces for adults. Adults are also allowed to store no more than five ounces in a locked trunk, glovebox or a locked container in their homes. Cafferelli also highlighted that purchased marijuana needed to remain in its original packaging and be out of reach of children.

The state legalized the recreational use of cannabis via the legislature in 2021. Since then, the state has recorded steady sales. Thus far, the adult-use market has seen a number of consecutive record-setting months of legal purchases. For instance, the state recorded $10.8 million worth of medical marijuana sales and $14.4 million in adult-use sales in September.

It is important to remember that the limits imposed on the purchase of products besides raw marijuana flower are set by equivalence.

Earlier in August, the state also launched a fund to provide support to social equity cannabis businesses. The established loan program will offer financial assistance to help individuals who have been disproportionately affected by the war on drugs to expand their businesses in this burgeoning industry.

In addition, in July of this year, the state legalized home cultivation of cannabis for personal use. It also adopted tax breaks for legal marijuana businesses in the same month. This move to help businesses that cannot make federal deductions under the IRS 280E code is expected to bring in $4.7 million in industry relief for the 2024 fiscal year. Projections from the office of the governor expect this figure to increase in the 2025 fiscal year, reaching $6.2 million.

The growth that is likely to result from this recent adjustment to how much recreational marijuana adults can buy could create opportunities for many local companies to grow to the levels experienced by companies that are licensed in other jurisdictions, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED).

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Two years ago, MariMed, a Massachusetts-based multistate cannabis operator, decided to establish a cannabis delivery service within its home state. Following comprehensive research on existing marijuana carrier services, the company contemplated two primary strategies: initiate a delivery service from scratch or look into acquiring an existing delivery company in Massachusetts.

Ultimately, MariMed opted to invest in Little Dog Delivery, and the two entities formed a strategic partnership. The essence of the partnership was MariMed’s aspiration for Little Dog to function as an extension of Panacea Wellness, the trio of retail establishments that MariMed owns in eastern Massachusetts.

Presently, Little Dog boasts a fleet of three delivery vans, each assigned to one of the Panacea Wellness locations, and operates under the moniker Panacea Delivery Powered by Little Dog. The delivery radius encompasses a 25-mile span around MariMed’s three dispensaries, covering eastern Massachusetts from the New Hampshire border down to Cape Cod. To incentivize customers, there is a nominal $10 delivery fee, which is waived for orders exceeding $200.

Operating the delivery service involves specific requirements stipulated by the state. These include equipping the delivery vehicles with GPS and a partition segregating the cannabis products from the driver. Moreover, the law mandates that a second employee accompany the driver in the passenger seat.

Ryan Crandall, MariMed’s chief revenue officer, reveals that the company has observed a consistent uptick in transactions each month. He states that the delivery consumer base is high-value and more loyal, with their average order value typically surpassing that of in-store shoppers.

To boost the delivery business, MariMed fosters partnerships with local businesses, such as yoga studios, to whom it gives discount codes to distribute among employees. According to Crandall, the keys to success in cannabis delivery include punctuality, effective communication, discounts and establishing loyalty reward programs.

Following the success of its venture in Massachusetts, MariMed expanded its delivery services to Delaware, another market under its purview. However, unlike in Massachusetts where MeriMed partnered with an existing business, the company established the Delaware delivery service from scratch, seamlessly integrating it into its existing medical retail model.

Despite maintaining a semblance of standard operating procedures across delivery services, certain variations arise due to differing state regulations. Delaware, for example, only mandates one employee per delivery vehicle, in contrast to Massachusetts, which necessitates a driver be accompanied by a second person.

Though MariMed has yet to introduce delivery services in Illinois, its third operating state, Crandall anticipates the eventuality of offering delivery to consumers in the state and seeks to be well prepared for that opportunity.

MeriMed’s evolution shows how numerous marijuana companies, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), are nimble and leverage any opportunities that come their way in order to deepen their penetration of the market.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Several medical cannabis companies in Hawaii have pioneered a new sales route in the state that involves delivering wholesale cannabis flower and other cannabis products from one island to another. Hawaii legalized medical cannabis in 2000 via the state legislature and has only eight licensed medical marijuana dispensaries scattered across the archipelago.

The island state’s unique topography may have allowed for the growth of this new sales route as medical marijuana businesses strived to increase their reach and serve as many Hawaiians as possible.

Hopping between islands by boat, helicopter or plane is common for both residents and visitors, and cannabis businesses in the state are leveraging established transportation pathways to deliver their products across various islands. Although these businesses haven’t been quick to share how they move their products between islands, likely to avoid legal and other issues, it is clear that they are island hopping to serve the thousands of medical marijuana patients in the state as efficiently as possible.

This new process is in a legal gray area because traveling between islands in Hawaii requires moving across federal waters — and federal law still outlaws cannabis. Hawaii legislators allowed cannabis operators in the state to island hop in June when they legalized wholesale marijuana sales by state-licensed firms to cannabis businesses on other islands. The interisland trade route officially became legal in August, and cannabis operators in Hawaii have been quick to take advantage.

Big Island Grown was the first company to complete Hawaii’s first cannabis wholesale interisland deal with Kauai-based Green Aloha dispensary. Green Aloha sold out of Big Island Grown’s cannabis flower in only slightly over a week at its dispensaries in Koloa and Kappa, Big Island Grown CEO Jaclyn Moore says.

Big Island Grown is also the sole licensed hydrocarbon extractor in Hawaii, and it is currently seeking Hawaii State Department of Health approval to deliver concentrates such as live resin vape pens and gummies wholesale to retailers. Moore says the cannabis company noticed a market for cannabis concentrates on the other islands that don’t have hydrocarbon extractors. The company now supplies around 30% of all weighted marijuana products in the Hawaiian market, Moore says.

Moore declined to discuss specific details on logistics and cannabis transportation, citing worker safety and the inherent sensitivity of the issue.

Big Island Grown and other companies may be using commercial flights and island-hopper planes, commercial boats and private charters to move their products between islands.

Given the challenging operational environment that cannabis companies often have to contend with, it isn’t surprising that island hopping has become the norm. Even large companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) operating in large markets such as Canada also have their own regulatory issues to navigate.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

A recent study, featured in the JAMA Open Network, has shed light on the impact of marijuana legalization in Canada, specifically concerning its effects on young individuals and potential adverse consequences. The research, conducted in Ontario, focused on a cohort of young adults aged between 19.5 to 23 years, aiming to understand changes in marijuana consumption patterns and related outcomes. Over the span of three years, from February 2017 to February 2020, the researchers conducted surveys every four months, collecting data that encompassed both the pre- and post-legalization periods.

The study involved 619 participants, with an average age of 21 and a standard deviation of 1.2 years. Approximately 56% were female, and 53% held bachelor’s degrees at the latest recorded time point. Notably, before legalization, around 33% reported occasional marijuana use as the norm.

Contrary to concerns about a surge in marijuana use among young people following legalization, the study revealed an overall reduction in marijuana use. This decline in consumption aligns with the existing substance-use patterns within this age group, unaffected by the policy change brought about by legalization.

Interestingly, the most frequent marijuana users before legalization experienced a significant decrease in usage following the legal transition. Consequently, there was a marked decrease in cannabis-related adverse consequences reported among the group. This suggests that the legalization of marijuana may have led to more responsible use among those who were previously heavy users.

On the other hand, individuals who abstained from cannabis use in the period leading up to legalization exhibited a modest but noteworthy increase in consumption over time. Importantly, this increase in use did not result in a corresponding surge in adverse consequences, challenging the notion of increased risks associated with cannabis legalization.

Those who had refrained entirely from using cannabis before legalization experienced no significant increases in negative consequences or usage post-legalization. These observations highlight the complexity of factors influencing marijuana use among young adults and suggest that further research is necessary to fully understand the determinants at play.

This study represents the first longitudinal analysis of the impact of marijuana legalization on young adults in Canada, incorporating multiple time points both before and after legalization.

It is, however, consistent with several U.S. studies that show state marijuana legalization has not significantly changed the consumption habits of adolescents and young people. Over the past 10 years, federal and state data have consistently shown a drop in the overall rate of youth marijuana usage.

This study goes to show that those who regard cannabis companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) as possibly doing harm to youth have no justification for their attitude to marijuana legalization.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Contenders of a proposed measure aiming to legalize cannabis in Germany faced a setback as they failed to garner sufficient support to thwart its progression through the legislative process. Germany’s legislative framework comprises two main chambers: the Bundesrat (also known as the Federal Council), comprising individual states’ representatives, and the Bundestag, which comprises democratically elected legislators. The legalization measure was presented in the Bundesrat, where lawmakers advocated for amendments but were unable to halt its advancement.

Germany’s federal cabinet, from whom the measure originally came, will now respond to the Bundesrat’s input before sending the law to the Bundestag for potential approval.

The motion to pause the legislation made by the Bavarian Bundesrat Rep. was rejected, as was a proposal to need the formal approval of the Bundesrat prior to legalization. Another attempt to raise the current draft’s 18-year-old legal possession age limit was similarly unsuccessful. However, there was consensus among the state representatives that the bill had a systemic enforcement weakness. They are seeking amendments to ensure that the states are not burdened with administrative expenditures associated with the federal government’s implementation of regulations.

The legalization proposal received 80 amendments from Bundesrat committees, including proposals to address drunk driving, prohibit alcohol sales and use in marijuana clubs, and set safety requirements for growing facilities.

The cabinet is expected to issue a counterstatement, after which the bill will proceed to the Bundestag. If it passes there, the Bundesrat can debate the measure but cannot block its implementation.

If enacted, the bill would permit adults 18 years of age and older to legally possess marijuana and grow up to three cannabis plants for personal use. Furthermore, the proposal introduces social clubs to distribute cannabis to members, with purchase caps of 25 grams per day for those older than 21 years of age and 30 grams monthly for those aged 18 to 21. The clubs cannot be established within a 200-meter radius of educational institutions or playgrounds. There are also specific limits on the number of clubs per district or city.

The bill also includes cost estimates for program implementation, potential savings from reduced enforcement and expected new revenue collected through employment taxes.

Germany’s journey toward legalization involved months of internal discussions and negotiations, complemented by visits to California marijuana businesses. Additionally, high-level meetings with European counterparts signaled a commitment to ending cannabis prohibition and regulating the industry.

As more markets such as Germany open on the European continent, enterprises such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) could have a larger international market to expand into.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

California’s cannabis companies are urging Governor Gavin Newsom to reject a recently passed measure aimed at dissuading children from accessing marijuana products. The businesses argue that the bill would result in the prohibition of the current branding of numerous established products while failing to address the persisting issue of the black market.

Last week, the California Assembly passed AB 1207, which effectively bans any packaging or labeling of marijuana products deemed “enticing to minors.” This bill defines such packaging as any promotional material featuring elements such as cartoons, toys, robots, fictional or real humans, animals, fruits, vegetables, or anything else that regulators believe might appeal to individuals under 21 years old.

Supporters of the bill, including youth advocates, argue that it is necessary in light of the recent uptick in cases of children accidentally consuming marijuana products, some of which have been designed to resemble popular snacks and candies.

According to Zack Kaldveer, spokesperson for the California Public Health Institute, there has been a notable increase in child poisonings and hospitalizations due to such accidental exposures. The California Poison Control reported a surge in annual cannabis exposures, with numbers rising from fewer than 200 in 2010 to more than 1,600 in 2020, with nearly one-half of these cases involving children.

However, the vast majority of cannabis advocacy groups are firmly against the bill, fearing it may inadvertently exacerbate public safety issues rather than mitigate them.

Should the bill be enacted, the California Marijuana Industry Association estimates that most marijuana businesses would be burdened with costs ranging from $100,000 to $300,000 to redesign their product labels. Furthermore, industry insiders argue that the bill’s scope is overly broad, targeting benign packaging of established brands while letting illicit operators off the hook.

Critics point out that the illicit market frequently mimics well-known cereal, candy and snack brands — a practice already prohibited in the legal cannabis industry — and that these products are regularly sold to children by black-market operators.

Newsom has already signed three drug policy-related bills during this legislative session without issuing any vetoes. One measure includes provisions that grant immunity to individuals in possession of personal-use quantities of controlled substances if they test them for contaminants such as fentanyl, report positive results to law enforcement and provide details about the source of the substance. The second measure empowers the State Water Board to investigate suspected illegal cannabis cultivators and participate in enforcement actions, while a third measure alters background check requirements for cannabis businesses.

The proposed change to the marijuana-product labeling rules in California could be of great concern to major industry actors such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) since other jurisdictions could follow these extreme restrictions and enact them as well, compelling licensed companies to walk an even tighter rope in a bid to adhere to all the applicable laws in the jurisdictions in which they operate.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Cannabis Exchange-Traded Funds (ETFs) surged in value in September as positive federal action renewed investor interest in the cannabis industry. Shortly after the U.S. Department of Health and Human Services recommended that the Drug Enforcement Administration (DEA) reclassify cannabis to Schedule III from Schedule I and ease federal marijuana restrictions, marijuana-related ETFs began to soar as investors started investing in the cannabis industry.

America’s state-legal cannabis sector is the fastest-growing sector in the nation, generating billions of dollars in yearly revenue. However, the industry has been consistently handicapped by federal regulation. Federal law still classifies cannabis as a Schedule I drug with no medical application, which has made operating in the state-level industry extremely difficult. Issues like limited access to banking services and federal financial aid are prevalent throughout the industry and have likely prevented investors from investing in the cannabis sector.

For example, the Poseidon Dynamic Cannabis ETF by AdvisorShares went down in August amid declining investor interest in marijuana. The fund’s comanager Morgan Paxhia said at the time that the closure of the fund was partly due to a “dramatic shift in investor sentiment” that has affected the nation’s state-level marijuana industry.

Now that federal lawmakers are flirting with the idea of decriminalizing and possibly legalizing the quasilegal sector at the federal level, investor interest is rising. Last week, AdvisorShares Pure US cannabis (MSOS) was up by 56% and ETFMG Alternative Harvest (MJ) soared by 47% while both the SP 500 and the Dow Jones Industrial Average were up by just around 0.5%,

Matt Bottomley, an analyst from financial services firm Canaccord Genuity, noted that federal headlines often act as catalysts for how certain stocks trade. He observed that recent cannabis-related headlines had a positive effect on cannabis ETFs.

The Biden administration’s recommendation for cannabis reclassification at the federal level also caused the shares of cannabis companies such as Cronos Group, Tilray Brands and Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) to surge. This has been a boon for cannabis equities, which have suffered from a capital crunch in recent years as many investors withdrew from the industry.

Despite extensive legalization at the state level, federal prohibition has consistently been a thorn in the cannabis industry’s side, limiting the sector’s access to financing and preventing it from expanding to broader markets. The prospect of finally legalizing cannabis at the federal level and eliminating the barriers that limit trade in the sector will likely attract more investors to cannabis-related equities.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

President Joe Biden’s stance on the medical use of marijuana has been unequivocal, as affirmed by the White House amid an ongoing federal review of cannabis scheduling. In a recent press briefing, Karine Jean-Pierre, White House press secretary, addressed inquiries regarding the potential ramifications of reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

The U.S. Department of Health and Human Services (HHS) recently recommended this reclassification to the U.S. Drug Enforcement Administration (DEA).

Jean-Pierre, exercising caution, refrained from preempting the process. She emphasized, “I don’t want to anticipate events; I’ve encountered this query previously.” She clarified, “Let me be clear: The president directed both the HHS secretary and the attorney general to initiate the administrative evaluation of marijuana’s scheduling, as you have outlined.”

Nonetheless, Jean-Pierre reiterated the president’s endorsement of federal cannabis reform, particularly concerning medical marijuana. Biden’s support for cannabis reform has not been unwavering. During his tenure as a senator, he championed legislation that intensified the war on drugs.

Should the DEA concur with HHS’s Schedule III recommendation, it would signify a pivotal shift in federal cannabis policy. The reclassification would acknowledge that cannabis possesses low potential for abuse and offers medical utility. However, it would not endorse existing state-level medical marijuana programs. Nevertheless, it would facilitate expanded research into the plant and have substantial implications for the marijuana industry.

Bipartisan congressional representatives have applauded the health agency’s recommendation, viewing it as a significant stride toward federal legalization. Some have even claimed credit for this advancement, citing their years of advocacy for marijuana reform.

Despite the enthusiasm surrounding this development, the scheduling decision remains tentative. The DEA has stated that it will initiate its review, factoring in findings from the FDA. Ultimately, the DEA retains the authority to decide on the reclassification to Schedule III.

From a political perspective, moving cannabis from Schedule I to III would allow the president to assert his role in achieving a substantial reform, facilitating an administrative evaluation more than half a century after cannabis was categorized as the most restrictive substance during the government’s war on drugs. However, it would not fulfill his campaign promise to decriminalize cannabis.

The reform could also invigorate momentum for congressional initiatives aimed at altering federal marijuana laws, such as the cannabis banking reform bill listed among the legislative priorities of Chuck Schumer, the Senate Majority Leader, according to a recent Dear Colleague letter.

As broader cannabis policy reforms take shape, industry actors such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) could be poised for explosive growth as the market is opened across the country.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Recent research suggests that lesser-known cannabinoids derived from marijuana and hemp, such as CBN, CBM, CBC, CBDV and THCV, might hold promise in treating dermatological conditions INCLUDING acne, psoriasis and eczema. The study, published recently in the peer-reviewed journal “Molecules,” highlights the potential therapeutic value of these minor cannabinoids in managing skin disorders as well as presenting new avenues for patient care and well-being enhancement.

The research, led by Polish scholars Dorota Kowalczuk and Emilia Kwiecień, involved an extensive review of existing scientific literature. The team observed that minor cannabinoids exhibit a range of pharmacological activities, encompassing anti-itch, analgesic, antimicrobial and anti-inflammatory properties. These cannabinoids have also shown efficacy in alleviating symptoms linked to various dermatological issues, including pruritus, acne, eczema and psoriasis.

Some minor cannabinoids appeared particularly suited for targeting specific skin conditions. For instance, CBDV, due to its anti-inflammatory characteristics, can potentially soothe itching and inflammation related to atopic dermatitis. Additionally, its antioxidant properties could aid in healing acne lesions.

Similarly, other recently identified cannabinoids such as CBE and CBM display anti-inflammatory potential and open new avenues for research into targeted disease conditions. CBC, known for its anti-inflammatory and antioxidant effects, may offer benefits for treating psoriasis, acne and atopic dermatitis.

THCV stands out for its potential in combating acne because it appears to regulate sebum production. Its anti-inflammatory and antibacterial attributes contribute to alleviating inflammation and targeting bacteria linked to acne development.

The researchers highlighted the therapeutic potential of minor cannabinoids, including cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), tetrahydrocannabivarin (THCV), cannabichromene (CBC), cannabidiforol (CBDP) and cannabidivarin (CBDV), as well as newer discoveries such as cannabielsoin (CBE) and cannabimovone (CBM).

The effects are believed to stem from interactions between cannabinoids and the body’s endocannabinoid system, a central regulatory mechanism crucial for maintaining organism health and function. This system plays a pivotal role in regulating skin functions, immune responses, cell differentiation, proliferation and survival, thereby effectively mitigating skin inflammation. Furthermore, topical application of these minor cannabinoids may hold promise for mitigating aging-related effects on the skin.

However, the researchers caution that more in-depth research is essential to validate their safety and effectiveness. Multiple challenges, including impact on the nervous system, product quality and regulation concerns, and ethical and legal considerations, need comprehensive exploration.

They concluded that despite the encouraging therapeutic potential, the utilization of cannabinoids, particularly minor ones, requires continued research, stringent regulations and a balanced approach to maximize benefits while minimizing any potential risks to health and society.

Companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) selling marijuana for both medical and recreational use could be helping people combat more symptoms or conditions than the patients themselves intend.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.